MDXG Mimedx Group Inc
Price (delayed)
$8.4
Market cap
$1.23B
P/E Ratio
13.33
Dividend/share
N/A
EPS
$0.63
Enterprise value
$1.16B
MiMedx is an industry leader in utilizing birth tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
Highlights
The debt has plunged by 61% YoY
The quick ratio has increased by 14% YoY and by 12% QoQ
Key stats
What are the main financial stats of MDXG
Market
Valuations
Earnings
Shares outstanding
146.95M
Market cap
$1.23B
Enterprise value
$1.16B
Price to earnings (P/E)
13.33
Price to book (P/B)
6.81
Price to sales (P/S)
3.6
EV/EBIT
16.46
EV/EBITDA
15.35
EV/Sales
3.4
Revenue
$342.81M
Gross profit
$285.8M
Operating income
$74.36M
Net income
$93.64M
EBIT
$70.75M
EBITDA
$75.89M
Free cash flow
$55.83M
Per share
Balance sheet
Liquidity
EPS
$0.63
EPS diluted
$0.6
Free cash flow per share
$0.38
Book value per share
$1.23
Revenue per share
$2.33
TBVPS
$1.45
Total assets
$243.89M
Total liabilities
$62.88M
Debt
$19.02M
Equity
$181.01M
Working capital
$130.2M
Debt to equity
0.11
Current ratio
4.1
Quick ratio
3.41
Net debt/EBITDA
-0.92
Margins
Efficiency
Dividend
EBITDA margin
22.1%
Gross margin
83.4%
Net margin
27.3%
Operating margin
21.7%
Return on assets
40.1%
Return on equity
57.8%
Return on invested capital
61%
Return on capital employed
35%
Return on sales
20.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MDXG stock price
How has the Mimedx Group stock price performed over time
Intraday
1.45%
1 week
1.08%
1 month
-2.44%
1 year
4.09%
YTD
-12.68%
QTD
-12.68%
Financial performance
How have Mimedx Group's revenue and profit performed over time
Revenue
$342.81M
Gross profit
$285.8M
Operating income
$74.36M
Net income
$93.64M
Gross margin
83.4%
Net margin
27.3%
The operating income has soared by 126% YoY
The operating margin has soared by 105% YoY
MDXG's gross profit is up by 13% year-on-year
MDXG's revenue is up by 11% YoY
Growth
What is Mimedx Group's growth rate over time
Valuation
What is Mimedx Group stock price valuation
P/E
13.33
P/B
6.81
P/S
3.6
EV/EBIT
16.46
EV/EBITDA
15.35
EV/Sales
3.4
The stock's price to earnings (P/E) is 6% less than its last 4 quarters average of 14.2
The P/B is 8% higher than the last 4 quarters average of 6.3
Mimedx Group's equity has increased by 8% QoQ
The P/S is 38% higher than the 5-year quarterly average of 2.6 and 20% higher than the last 4 quarters average of 3.0
MDXG's revenue is up by 11% YoY
Efficiency
How efficient is Mimedx Group business performance
Mimedx Group's return on equity has decreased by 28% QoQ
MDXG's ROA is down by 6% QoQ
Dividends
What is MDXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MDXG.
Financial health
How did Mimedx Group financials performed over time
The total liabilities has contracted by 34% YoY
The total assets has grown by 29% YoY and by 6% from the previous quarter
The debt is 89% less than the equity
MDXG's debt to equity has dropped by 100% year-on-year
The debt has plunged by 61% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.